Due Diligence Essentials When Acquiring a Pharma Company

Acquiring a pharmaceutical business can accelerate growth dramatically. Ready manufacturing licences, product registrations, established brands and installed capacity can take years to build from scratch. But pharma acquisitions also carry risks that do not appear in financial statements. A certificate about to expire, a critical inspection observation or a data integrity problem can change the value of a deal overnight.

This guide outlines what a complete pharma due diligence should cover and how to use the findings to protect value.

Start With the Deal Thesis

Before diving into data rooms, be clear about why you are buying. Are you acquiring capacity, registrations in specific markets, a brand portfolio, technical capabilities or a customer base? The deal thesis determines which areas deserve the deepest review and which risks would be deal breakers.

Regulatory Due Diligence

• Validity and scope of manufacturing licences and product permissions
• GMP certificates, inspection history, observations and CAPA status
• Status and renewal dates of product registrations in each export market
• Pending variations, renewals and regulator correspondence
• Pharmacovigilance systems and any safety issues

Ask for full inspection reports and responses, not just certificates. The detail of observations and the quality of responses reveal much more about compliance maturity.

Technical and Quality Review

Assess the condition of facilities, equipment and utilities, as well as the maturity of the quality system. A site visit by experienced technical experts is essential.

• Condition and remaining life of buildings, HVAC and water systems
• Equipment capacity, utilisation and maintenance history
• Validation status of processes, cleaning and computerised systems
• Data integrity practices, including audit trails and access control
• Deviation, complaint and recall history
• Capex needed to meet current or target regulatory standards

Commercial Assessment

• Revenue concentration by product, customer and market
• Pricing pressure and exposure to price controlled products
• Distribution agreements and change of control clauses
• Pipeline of products under development or registration
• Brand strength and market share in key segments

Financial and Legal Review

Standard financial diligence covers quality of earnings, working capital, debt and tax exposures. In pharma, also check inventory for short expiry or obsolete stock, provisions for returns and recalls, and the true cost of maintaining compliance. Legal review should cover property titles, environmental approvals, litigation, intellectual property and employment matters.

Key Risk Areas and Their Impact

Finding	Potential impact	Typical response
Critical inspection observations	Loss of certification or export access	Price adjustment, conditions precedent
Data integrity gaps	Regulatory action, remediation cost	Remediation plan, escrow or indemnity
Expiring registrations	Revenue loss in key markets	Renewal as closing condition
Customer concentration	Revenue volatility	Earn out structure

Using Findings in Negotiation

Due diligence findings should feed directly into deal terms. Depending on the issue, options include price adjustments, specific indemnities, escrow arrangements, earn outs, warranties and conditions that must be satisfied before closing. Quantify remediation costs wherever possible so that negotiations are based on evidence rather than opinion.

In pharma, regulatory and quality findings can change the value of a deal more than financial numbers.

Integration Planning

Value is created after closing. Plan quality system harmonisation, people and culture integration, IT systems and portfolio rationalisation before the deal is signed. Regulatory filings for changes of ownership, site transfers or licence amendments should be mapped with realistic timelines, so that supply continuity is protected throughout the transition.

Running the Due Diligence Process

1. Agree scope, priorities and deal breakers based on the deal thesis.
2. Issue a detailed information request list covering all workstreams.
3. Review data room documents and prepare follow up questions.
4. Conduct site visits and management interviews.
5. Quantify findings and remediation costs.
6. Prepare a consolidated report with recommendations for deal terms.

Environmental, Health and Safety

Pharmaceutical sites handle solvents, active ingredients and waste streams that require environmental consents and safe handling. Review pollution control approvals, effluent treatment performance, hazardous waste records, fire safety certificates and any history of incidents. Remediation of environmental issues can be costly and can affect operating permissions.

People and Key Talent

Much of a pharma company’s value sits with experienced quality, regulatory and technical staff. Identify key people early, understand their roles and plan retention arrangements so that knowledge and relationships are preserved after closing.

Common Deal Structures

Pharma transactions are commonly structured as share purchases, where the buyer acquires the legal entity with its licences and registrations, or asset purchases, where selected assets such as a plant, brands or dossiers are transferred. Share purchases keep licences and registrations in place but bring all historical liabilities. Asset purchases allow the buyer to choose what to acquire but require licence and registration transfers, which take time and regulatory approval.

The right structure depends on the target’s compliance history, the value of its registrations, tax considerations and the buyer’s appetite for inherited risk. Due diligence findings often shape this choice, which is why structure discussions should begin early in the process.

After Closing: The First Hundred Days

Use the first hundred days to secure compliance, stabilise the team and communicate clearly with customers, suppliers and regulators. Address any critical quality findings immediately, confirm regulatory notifications of ownership changes, and track progress against the integration plan agreed before signing.

Questions to Ask Management

• What were the most significant findings in recent inspections, and how were they closed?
• Which registrations are due for renewal in the next two years?
• Which products depend on a single API supplier or a single customer?
• What capital investment is planned or needed to maintain compliance?
• Which people are critical to operations, quality and customer relationships?

Honest answers to these questions often reveal more than any single document in the data room.

Compare these answers with the documents you review and the observations from the site visit. Where stories and evidence differ, dig deeper. Consistency between what management says, what records show and what experts observe on the shop floor is one of the strongest indicators of a well run pharmaceutical business and a sound investment.

Zanax Healthcare supports investors and pharma companies with target screening, technical and regulatory due diligence, deal support and post merger integration.